1. Medtech Insight
  2. >>Archive

Permanent LVAD Implants Appropriate For End-Stage Heart Failure – CMS

Left-ventricular assist device implants for destination therapy will be limited to 60 U.S. centers under the terms of a positive CMS national coverage determination for the therapy, Thoratec estimates

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight